SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alembic Pharma strengthens on reporting stellar numbers for Q2FY16

27 Oct 2015 Evaluate

Alembic Pharmaceuticals is currently trading at Rs. 685.00, up by 6.55 points or 0.97 % from its previous closing of Rs. 678.45 on the BSE.

The scrip opened at Rs. 685.50 and has touched a high and low of Rs. 708.00 and Rs. 677.05 respectively. So far 178879 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 791.70 on 15-Jul-2015 and a 52 week low of Rs. 381.90 on 26-Feb-2015.

Last one week high and low of the scrip stood at Rs. 726.45 and Rs. 674.50 respectively. The current market cap of the company is Rs. 12894.49 crore.

The promoters holding in the company stood at 74.13% while Institutions and Non-Institutions held 12.60 % and 13.28% respectively.

Alembic Pharmaceuticals has over three fold jump in its net profit after tax at Rs 252.67 crore for the quarter ended September 30, 2015 as compared to Rs 84.05 crore for the same quarter in the previous year. The company’s total income has increased by 70.37% to Rs 922.59 crore for the quarter under review from Rs 541.52 crore for the corresponding quarter of the previous year.

On the consolidated basis, the company has reported over three fold jump in its net profit/(loss) after tax and share of profit of associates at Rs 288.90 crore for the quarter ended September 30, 2015 as compared to Rs 77.27 crore for the same quarter in the previous year. Total income of the company has increased by 84.35% at Rs 1008.81 crore for quarter under review as compared to Rs 547.22 crore for the quarter ended September 30, 2014. 

Alembic Pharma Share Price

755.75 -3.25 (-0.43%)
21-Apr-2026 10:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1674.30
Dr. Reddys Lab 1225.00
Cipla 1231.55
Zydus Lifesciences 929.90
Lupin 2326.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×